Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Cash & Equivalents (2020 - 2026)

Barinthus Biotherapeutics filings provide 7 years of Cash & Equivalents readings, the most recent being $65.9 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 33.56% to $65.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $65.9 million, a 33.56% decrease, with the full-year FY2025 number at $70.5 million, down 36.33% from a year prior.
  • Cash & Equivalents hit $65.9 million in Q1 2026 for Barinthus Biotherapeutics, down from $70.5 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $200.6 million in Q1 2022 to a low of $65.9 million in Q1 2026.
  • Median Cash & Equivalents over the past 5 years was $123.9 million (2024), compared with a mean of $135.8 million.
  • Biggest five-year swings in Cash & Equivalents: grew 28.64% in 2022 and later tumbled 36.33% in 2025.
  • Barinthus Biotherapeutics' Cash & Equivalents stood at $194.4 million in 2022, then fell by 17.53% to $160.3 million in 2023, then plummeted by 30.97% to $110.7 million in 2024, then tumbled by 36.33% to $70.5 million in 2025, then dropped by 6.53% to $65.9 million in 2026.
  • The last three reported values for Cash & Equivalents were $65.9 million (Q1 2026), $70.5 million (Q4 2025), and $74.3 million (Q3 2025) per Business Quant data.